AU2001271867A1 - Methods for treatment of conditions affected by activity of multidrug transporters - Google Patents

Methods for treatment of conditions affected by activity of multidrug transporters

Info

Publication number
AU2001271867A1
AU2001271867A1 AU2001271867A AU7186701A AU2001271867A1 AU 2001271867 A1 AU2001271867 A1 AU 2001271867A1 AU 2001271867 A AU2001271867 A AU 2001271867A AU 7186701 A AU7186701 A AU 7186701A AU 2001271867 A1 AU2001271867 A1 AU 2001271867A1
Authority
AU
Australia
Prior art keywords
activity
treatment
methods
conditions affected
multidrug transporters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271867A
Inventor
Eve M. Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Neotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotherapeutics Inc filed Critical Neotherapeutics Inc
Publication of AU2001271867A1 publication Critical patent/AU2001271867A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001271867A 2000-07-07 2001-07-06 Methods for treatment of conditions affected by activity of multidrug transporters Abandoned AU2001271867A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21661600P 2000-07-07 2000-07-07
US60216616 2000-07-07
PCT/US2001/021383 WO2002004449A2 (en) 2000-07-07 2001-07-06 Methods for treatment of conditions affected by activity of multidrug transporters

Publications (1)

Publication Number Publication Date
AU2001271867A1 true AU2001271867A1 (en) 2002-01-21

Family

ID=22807783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271867A Abandoned AU2001271867A1 (en) 2000-07-07 2001-07-06 Methods for treatment of conditions affected by activity of multidrug transporters

Country Status (3)

Country Link
US (1) US20020128264A1 (en)
AU (1) AU2001271867A1 (en)
WO (1) WO2002004449A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
US20040265323A1 (en) * 2003-05-16 2004-12-30 Mccormick Beth A. Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
WO2005030148A2 (en) * 2003-09-25 2005-04-07 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
AU2005226359B2 (en) * 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939202A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Novel adenine compound
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
JPWO2007034916A1 (en) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co Novel adenine compound
EP1939199A4 (en) * 2005-09-22 2010-10-20 Dainippon Sumitomo Pharma Co Novel adenine compound
JP2009542645A (en) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ 8-oxoadenine derivatives acting as modulators of TLR7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
EP2139894B1 (en) * 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
SI2132209T1 (en) * 2007-03-19 2014-05-30 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
WO2008114819A1 (en) * 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. Novel adenine compound
BRPI0811125A2 (en) * 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolines with immunomodulatory properties
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
PE20091236A1 (en) * 2007-11-22 2009-09-16 Astrazeneca Ab PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7
UY31531A1 (en) 2007-12-17 2009-08-03 SALTS DERIVED FROM 8-OXOADENINE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY AS TOLL TYPE RECEIVER MODULATORS (TLR)
EP2246353A4 (en) * 2008-01-17 2011-04-20 Dainippon Sumitomo Pharma Co Method for producing adenine compound
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
BRPI1010937A2 (en) 2009-05-21 2019-09-24 Astrazeneca Ab compound, use of a compound, and method for treating cancer
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
EP2651943B1 (en) 2010-12-17 2017-03-22 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives
BR112014029261A2 (en) 2012-05-18 2017-06-27 Astrazeneca Ab carboxylic acid compounds
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091432A (en) * 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use

Also Published As

Publication number Publication date
WO2002004449A3 (en) 2002-06-13
WO2002004449A2 (en) 2002-01-17
US20020128264A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AU2001271867A1 (en) Methods for treatment of conditions affected by activity of multidrug transporters
AU1294401A (en) Methods for treating fibroproliferative diseases
AU2003249244A1 (en) Methods for the treatment of neoplasms
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2003297762A1 (en) Methods for treating essential tremor
AU2002215125A1 (en) Well treatment method
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2002228991A1 (en) Methods for treating diseases caused by deficiencies of alpha-l-iduronidase
AU2002362030A1 (en) Methods for inhibiting deacetylase activity
AU2003256655A1 (en) Therapeutic compounds for treating dyslipidemic conditions
AU2002336405A1 (en) Methods for treating deodorizer distillate
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2001286983A1 (en) Method of treatment
AU2001285747A1 (en) Method for the treatment of tobacco
AU2003222022A1 (en) Methods for treating deodorizer distillate
AU2001232263A1 (en) Method of treating seeds
AU2002217447A1 (en) Apparatus for lipolysis for aesthetic treatment
AU2001294258A1 (en) Method of purifying plavastatin
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
AU2003234921A1 (en) Method of knitting knit-wear
AU2001227697A1 (en) Method for purification of acetone
AU2002225327A1 (en) Apparatus for aesthetic treatment
AU2001262177A1 (en) Method of treatment
AU2001230365A1 (en) Method of screening compounds for biological activity
AU2003236232A1 (en) Method for treatment of textile